Accordingly, recent evidence suggests Tau protein as the final executor of AD neuronal dysfunction (Roberson et al., 2007; Ittner & Gotz, 2011) and, therefore, anti‐Tau therapies emerged as potential strategies against AD (Frost et al., 2015); however, their safety or potential risks have not been defined yet. The gene discussed is MAPT; the disease is Alzheimer disease.